Fluence Corporation Limited (ASX:FLC)

Market Cap	55.35M
Revenue (ttm)	83.21M
Net Income (ttm)	-34.58M
Shares Out	1.09B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	126.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	577,917
Average Volume	667,614
Open	0.0520
Previous Close	0.0580
Day's Range	0.0480 - 0.0550
52-Week Range	0.0300 - 0.1100
Beta	0.36
RSI	50.70
Earnings Date	Jul 29, 2025

About Revance Therapeutics

Fluence Corporation Limited, together with its subsidiaries, provides smart water and wastewater treatment solutions for the municipal, commercial, and industrial markets worldwide. The company offers water treatment solutions, such as reverse-osmosis desalination, clarification, multimedia filtration, methane removal, arsenic removal, denitrification, uv disinfection, softening, mollusk removal, coagulation and flocculation, flotation, activated carbon filtration, biological filtration, contaminants removal, ultrafiltration, remineralization, ...

• Industry: Pollution & Treatment Controls
• Sector: Industrials
• Founded: 2007
• Employees: 300
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: FLC

Financial Performance

In 2024, Fluence Corporation's revenue was $51.50 million, a decrease of -26.48% compared to the previous year's $70.05 million. Losses were -$21.40 million, 33.7% more than in 2023.